5. An important mechanism by which clinical resistance develops to imatinib in chronic myelogenous
leukemia is?
(A)increased excretion in the urine.
(B)increased hepatic metabolism.
(C)decreased bioactivation in cancer cells.
(D)spontaneous mutations in the BCR-ABL kinase.
答案:登入後查看
統計: A(0), B(0), C(0), D(4), E(0) #3224328
統計: A(0), B(0), C(0), D(4), E(0) #3224328